Policy / Pricing UniQure, Replimune shares rise as FDA’s Makary exits, but path forward unchanged BioSpaceAfter devastating regulatory setbacks last year, shares of uniQure and Replimune rose on the news that FDA Commissioner Marty Makary is leaving.Read full story pharminent May 13, 2026 (Last updated: May 13, 2026) BioSpace After devastating regulatory setbacks last year, shares of uniQure and Replimune rose on the news that FDA Commissioner Marty Makary is leaving. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Assertio accepts new buyout bid; AI biotech Isomorphic banks $2BNext: FDA’s leadership void leaves biotech with renewed ‘uncertainty’ Related Stories Policy / Pricing Decoding Medicare Advantage Coding Intensity pharminent July 1, 2026 Policy / Pricing UK partners with Eli Lilly on obesity plan pharminent June 29, 2026 Policy / Pricing EFPIA report adds to pressures on EU drug pricing policy pharminent June 24, 2026
